• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Meal-dependent absorption of enteric-coated sodium valproate.

作者信息

Levy R H, Cenraud B, Loiseau P, Akbaraly R, Brachet-Liermain A, Guyot M, Gomeni R, Morselli P L

出版信息

Epilepsia. 1980 Jun;21(3):273-80. doi: 10.1111/j.1528-1157.1980.tb04073.x.

DOI:10.1111/j.1528-1157.1980.tb04073.x
PMID:6769666
Abstract

The effect of meals on valproic acid (VPA) absorption from an enteric coated (EC) formulation was investigated. In study I, six adult normal volunteers received a single 500 mg dose of sodium valproate in randomized treatments: fasting (A), with a meal (B) or 3 hours after a meal (C). There were significant differences between treatments in the latency period (Lp) defined as the time during which measured concentrations of VPA were less than 1 microgram/ml. Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively. In study II, six subjects (five from study I) received in a randomized fashion a 400 mg intravenous bolus dose of VPA and a 500 mg EC VPA tablet, 3 hours after a meal. The mean Lp value was 8.1 +/- 1.6 hr and the mean bioavailability was 100%. Clearance, volume of distribution and half-life values obtained after intravenous dosing were comparable to literature values. These results indicate that food intake delays but does not decrease the extent of absorption of VPA from an enteric coated formulation.

摘要

相似文献

1
Meal-dependent absorption of enteric-coated sodium valproate.
Epilepsia. 1980 Jun;21(3):273-80. doi: 10.1111/j.1528-1157.1980.tb04073.x.
2
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.一项单剂量、三周期、六序列交叉研究,比较了空腹条件下健康墨西哥志愿者中镁丙戊酸盐溶液、混悬液和肠溶片剂的生物利用度。
Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.
3
Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
Clin Neuropharmacol. 1985;8(2):156-64. doi: 10.1097/00002826-198506000-00005.
4
Effect of food on the serum concentration profile of enteric-coated valproic acid.
Neurology. 1988 Aug;38(8):1319-22. doi: 10.1212/wnl.38.8.1319.
5
Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.丙戊酸钠缓释片与长效释放片的比较吸收曲线——临床意义
Ann Pharmacother. 2006 Apr;40(4):619-25. doi: 10.1345/aph.1G617. Epub 2006 Mar 28.
6
Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.三种丙戊酸口服制剂给予人体后的药代动力学。
Isr J Med Sci. 1984 Jan;20(1):46-9.
7
Bioavailability of a film-coated tablet of valproate in nonfasting volunteers.
Jpn J Psychiatry Neurol. 1987 Dec;41(4):693-8. doi: 10.1111/j.1440-1819.1987.tb00427.x.
8
Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).一种新型丙戊酸盐制剂的吸收特性:胶囊中的双丙戊酸钠包衣颗粒(德巴金速溶片)
J Clin Pharmacol. 1990 Aug;30(8):743-7. doi: 10.1002/j.1552-4604.1990.tb03637.x.
9
[Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
Arzneimittelforschung. 1986 Jul;36(7):1118-22.
10
Pharmacokinetics and bioavailability of sodium valproate.丙戊酸钠的药代动力学和生物利用度。
Clin Pharmacol Ther. 1977 Jun;21(6):736-43. doi: 10.1002/cpt1977216736.

引用本文的文献

1
Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.深入探讨丙戊酸的结构修饰及其药理学特性。
Molecules. 2021 Dec 24;27(1):104. doi: 10.3390/molecules27010104.
2
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.预防性治疗偏头痛药物的药代动力学变异性。
CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3.
3
Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.丙戊酸盐的药理和治疗特性:35年临床经验总结
CNS Drugs. 2002;16(10):695-714. doi: 10.2165/00023210-200216100-00004.
4
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.抗癫痫药物在儿科患者中的临床药代动力学。第一部分:苯巴比妥、扑米酮、丙戊酸、乙琥胺和甲琥胺。
Clin Pharmacokinet. 1995 Oct;29(4):257-86. doi: 10.2165/00003088-199529040-00005.
5
Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.癫痫患者丙戊酸稳态血浆浓度的昼夜变化。
Clin Pharmacokinet. 1982 Nov-Dec;7(6):544-52. doi: 10.2165/00003088-198207060-00004.
6
No effect of food intake on clobazam absorption.食物摄入对氯巴占吸收无影响。
Br J Clin Pharmacol. 1983 Dec;16(6):728-30. doi: 10.1111/j.1365-2125.1983.tb02251.x.
7
Clinical pharmacokinetics of valproic acid--1988.丙戊酸的临床药代动力学——1988年
Clin Pharmacokinet. 1988 Dec;15(6):367-89. doi: 10.2165/00003088-198815060-00002.
8
Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.抗惊厥药物的作用机制。II. 主要用于失神性癫痫的药物。
Eur J Pediatr. 1987 Jan;146(1):8-14. doi: 10.1007/BF00647274.